Opinion

Video

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alex Herrera, MD
Bertram Yuh, MD, MISM, MSHCPM
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
John L. Marshall, MD, of Georgetown Lombardi Comprehensive Cancer Center
October 28th 2024

ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

John H. Strickler, MD
October 23rd 2024

Telisotuzumab Adizutecan Delivers Early Signals of Antitumor Activity in CRC

Ravi Salgia, MD, PhD, professor, chair, Department of Medical Oncology & Therapeutics Research, Arthur & Rosalie Kaplan Chair in Medical Oncology & Therapeutics Research, City of Hope
September 2nd 2024

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

Thierry André, MD
October 16th 2024

Accurate Diagnosis of dMMR/MSI-H Status Is Key for Nivolumab/Ipilimumab Treatment in mCRC

Kristen K. Ciombor, MD, MSCI
October 11th 2024

Treatment Personalization Is Poised to Define New Era of mCRC Therapy